MedTrace Logo

Phase IV Observational Study of Orelabrutinib in the Treatment of Chronic Lymphocytic Leukemia/Small Cell Lymphoma

NCT05920668 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2023-06-27

No results posted yet for this study

Summary

This was a multicenter observational study of Orelabrutinib in the treatment of CLL/SLL. Patients were treated with Orelabrutinib for 12 cycles. The primary end points were grade 3 hypertension and incidence of atrial fibrillation, and the secondary end points were improvement in abnormal markers, ORR,CR,PFS, and OS.

Conditions

  • CLL/SLL

Interventions

DRUG

Orelabrutinib

Orelabrutinib monotherapy for CLL/SLL 12 cycles

Sponsors & Collaborators

  • Wang Xin

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-01
Primary Completion
2024-07-01
Completion
2025-07-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05920668 on ClinicalTrials.gov